• Arne Ferstad, born 1950, has broad experience of the biotech and pharma industries, including business development and international marketing. He has been in charge of Baxter Healthcare’s business in the Nordic and Benelux countries, served as President of EMEA Baxter Renal Division, managed Baxter’s bioscience business in Asia and he has held several senior positions within Baxter’s R&D. He has also served as General Manager and VP of Pharmacia Corporation.

  • Morten Albrechtsen, born 1964, has extensive experience in CNS drug development including drugs against Alzheimer’s (Enkam), depression (Boehringer Ingelheim), addiction (Nycomed, Saniona), pain control (Nycomed), insomnia (Blake Insomnia Inc. /Zleepax), and stroke (Boehringer Ingelheim, Enkam).
    His experience spans from pre-clinical and clinical development to regulatory approval and to post-approval commercialization, and comprises both biological products and small molecules.

  • Lars Thunberg, born 1966, is a co-founder of CombiGene and chaired its board during the period Aug. 2013 to Oct. 2014. He holds an MSc in Business Administration and Economics, Stockholm University and Lund University, and serves as chairman of several companies, for example VA Automotive AB (publ), which are listed on NASDAQ First North.

  • Peter Nilsson, born 1970, holds an MSc in Business Administration and Economics and is an authorized public accountant. He is a former partner and business area manager of Mazars SET Revisionsbyrå AB.
    Currently, Peter Nilsson is CFO of the Rotorbulk Group, also known as Finja.

  • Per Ericsson, born 1965, is a lawyer who specializes in IPR with the law firm of Advokatbyrån Gulliksson AB, where he has also held senior management positions since 2002.
    Previously, from 1998, he was a senior manager of the patent firm Ström & Gulliksson AB.

  • Morten Albrechtsen, born 1964, has extensive experience in CNS drug development including drugs against Alzheimer’s (Enkam), depression (Boehringer Ingelheim), addiction (Nycomed, Saniona), pain control (Nycomed), insomnia (Blake Insomnia Inc. /Zleepax), and stroke (Boehringer Ingelheim, Enkam).
    His experience spans from pre-clinical and clinical development to regulatory approval and to post-approval commercialization, and comprises both biological products and small molecules.